The Danish company announces that Britt Meelby Jensen has delivered her notice to resign from her position as President and CEO.
Britt Meelby Jensen has accepted a CEO position in a non-competing company outside Denmark and she will remain in her position with Zealand Pharma until further notice.
“I have sincerely enjoyed my four years at Zealand, working with an outstanding team and great partners. Zealand has gone through a transformation and has today a strong late stage pipeline and a solid financial position, with great potential to be unlocked over the next period. It has been a difficult decision to leave, but I have been offered an interesting position, where I can leverage a broader set of my competences,” says Britt Meelby Jensen, President and CEO of Zealand.
“Britt is leaving at a time, where Zealand is in a strong position, with clear priorities and financial strength to deliver on the company’s strategy. The Board is happy with the progress and the positive outlook for Zealand, and is fully committed to deliver on the strategic priorities. The Board is thankful for Britt’s contributions and wishes her all the best in her future endeavors,” says Martin Nicklasson, Chairman of Zealand.